Welcome to our dedicated page for Silo Pharma SEC filings (Ticker: SILO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Silo Pharma filings document a Nasdaq-listed Nevada operating company with common stock registered under symbol SILO and a developmental-stage biopharmaceutical business. Its registration statements and offering-related disclosures address registered securities, capital structure, smaller reporting company status, and securities transactions associated with a company developing CNS, psychiatric and chronic-pain therapeutic programs.
Recent 8-K and proxy filings record material agreements, equity issuances, shareholder voting matters, board and compensation-plan actions, and governance changes. Disclosures also cover asset purchases for QwikAgents and cryptocurrency-related software, formation of a cryptocurrency advisory board, registered and private securities transactions, and the amendment of the company’s 2020 omnibus equity incentive plan.
Silo Pharma, Inc. is registering for resale up to 1,906,392 shares of common stock held by selling shareholders. The registered shares comprise 124,000 already issued shares and shares issuable upon exercise of pre-funded, Series A-3, Series A-4 and placement agent warrants issued in a July 2026 private placement.
This is a resale registration; the company states it will not receive proceeds from share sales by the selling shareholders. It may receive cash only if the warrants associated with 1,782,392 of the registered shares are exercised, in which case it would receive the stated exercise prices. Following full cash exercise of those warrants, shares outstanding would be 3,035,002.
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency company, with lead drug candidate SPC-15 for PTSD and anxiety, plus additional preclinical programs for fibromyalgia, Alzheimer’s disease and CNS disorders. In June 2026 it completed a 1-for-15 reverse stock split, leaving 6,666,667 authorized common shares. The company reported a 2025 net loss of $4,227,698 and held $173,462 of crypto assets at fair value as of March 31, 2026.
Silo Pharma, Inc., a Nevada-based diversified developmental-stage biopharmaceutical and cryptocurrency company, has filed to register for resale up to 1,906,392 shares of common stock held by selling shareholders. The shares consist of 124,000 common shares issued in a July 2026 private placement and 1,782,392 shares issuable upon exercise of pre-funded, Series A-3, Series A-4 and placement agent warrants. This is a resale registration; the company will not receive proceeds from any sale of shares by selling holders.
The warrants are immediately exercisable at prices of $0.0001 (pre-funded), $6.21 (Series A-3 and A-4) and $8.065 (placement agent), with expirations ranging from 18 months to five years after effectiveness and subject to 4.99% or 9.99% beneficial ownership limits. If all 1,782,392 warrant shares registered here are exercised for cash, Silo estimates gross proceeds of approximately $8.07 million, intended for working capital and general corporate purposes. Assuming full cash exercise, common shares outstanding would be 3,035,002. Silo recently effected a 1-for-15 reverse stock split, reducing authorized common stock to 6,666,667 shares, and reported a 2025 net loss of $4,227,698 and a first-quarter 2026 net loss of $1,647,117. The company’s pipeline includes intranasal PTSD and Alzheimer’s candidates, a ketamine implant for fibromyalgia, and CNS peptide technology, alongside a crypto-asset treasury and staking strategy.
Silo Pharma, Inc., a Nevada biotechnology corporation based in Sarasota, Florida, conducted an exempt private securities offering in reliance on Rule 506(b). The company reported a total amount sold of $4,000,015 and a total remaining to be sold of $0.
H.C. Wainwright & Co., LLC acted as placement agent and received $300,002 in cash commissions plus warrants to purchase up to 46,497 shares of common stock at an exercise price of $8.065 per share. The initial sale in this offering occurred on July 9, 2026.
Silo Pharma, Inc. entered into securities purchase agreements with institutional investors for a private placement of its equity and warrants. The structure includes 124,000 shares of common stock at $6.452 per share and pre-funded warrants to purchase up to 495,965 shares of common stock at $6.4519 per warrant, together covering 619,965 shares. Investors also received Series A-3 and Series A-4 warrants to purchase up to 619,965 shares each, all with an exercise price of $6.21 per share, exercisable immediately, with expirations five years and eighteen months, respectively, after the effective date of a resale registration statement. Silo expects aggregate gross proceeds of about $4 million and net proceeds of approximately $3.5 million, and may receive up to roughly $7.7 million in additional gross proceeds if all warrants are exercised for cash. H.C. Wainwright & Co. acted as exclusive placement agent and received a cash fee and warrants for 46,497 shares at an exercise price of $8.065. Net proceeds are intended for working capital and general corporate purposes.
AdvisorShares Trust filed a Schedule 13G reporting beneficial ownership of 6.69% of Silo Pharma, Inc. The filing shows 75,582 shares of common stock (CUSIP 82711P300) as beneficially owned as of 06/30/2026. The report is signed by Stefanie Little, Chief Compliance Officer, on 07/08/2026.
Silo Pharma, Inc. is asking shareholders to vote at its 2026 annual meeting on August 14, 2026 at 11:00 a.m. Eastern in Sarasota, Florida. Holders of common stock as of June 18, 2026, when 1,128,610 shares were outstanding, may vote.
Shareholders will elect four directors, ratify Salberg & Company, P.A. as independent auditor for 2026, consider a common stock increase proposal, and approve a potential adjournment. The board is four members, three of whom are Nasdaq‑independent, and oversees audit, compensation, and nominating committees.
The proxy details executive compensation, including a $350,000 base salary for CEO Eric Weisblum and $60,000 for CFO Daniel Ryweck, plus stock option awards and severance terms for the CEO. It also describes the Amended and Restated 2020 Omnibus Equity Incentive Plan and current equity reserves.
Silo Pharma, Inc. has regained compliance with the Nasdaq minimum bid price requirement. Nasdaq’s Listing Qualifications Staff confirmed that the company’s common stock closed at or above $1.00 per share from June 3, 2026 through June 16, 2026, satisfying Listing Rule 5550(a)(2).
As a result, Silo’s common stock will continue trading on the Nasdaq Capital Market and Nasdaq now considers the matter closed. The company highlighted continued progress toward a first-in-human clinical trial for its PTSD candidate SPC-15 and ongoing development of its AI agents platform QwikAgents.
Silo Pharma, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders to be held on August 14, 2026 to vote on four proposals: election of four directors (Proposal 1), ratification of Salberg & Company, P.A. as auditor (Proposal 2), an increase in authorized common stock (Proposal 3), and an adjournment proposal (Proposal 4).
The Board unanimously recommends a vote FOR all four proposals. The record date for voting is June 18, 2026, and proxy materials will be made available beginning on or about June 30, 2026. Shares outstanding were 1,128,610 as of the record date; a quorum requires 376,205 shares. The company effected a 1-for-15 reverse stock split on June 2, 2026. Proxy voting instructions and methods are described in the notice and proxy card.